GlassScriptPhysician profile
Elizabeth J Blount
NPI 1912921313
$481.63
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $38.65 · 2021: $12.17.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $89.35 | 2019 | |
| Pfizer INC. | $77.47 | 2019 | |
| Merck Sharp & Dohme LLC | $54.00 | 2019 | |
| Novo Nordisk INC | $50.92 | 2019-2020 | |
| Glaxosmithkline, LLC. | $47.89 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $46.03 | 2019 | |
| Allergan, INC. | $35.52 | 2019-2020 | |
| Philips North America LLC | $20.97 | 2019 | |
| Lilly USA, LLC | $20.57 | 2019 | |
| Antares Pharma, INC. | $14.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.99 | 2019 | |
| Seqirus USA INC | $11.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Blount listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.